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Background: The receptor tyrosine kinase RON exhibits increased expression during pancreatic cancer progression
and promotes migration, invasion and gemcitabine resistance of pancreatic cancer cells in experimental models.
However, the prognostic significance of RON expression in pancreatic cancer is unknown.
Methods: RON expression was characterized in several large cohorts, including a prospective study, totaling 492
pancreatic cancer patients and relationships with patient outcome and clinico-pathologic variables were assessed.
Results: RON expression was associated with outcome in a training set, but this was not recapitulated in the
validation set, nor was there any association with therapeutic responsiveness in the validation set or the
prospective study.
Conclusions: Although RON is implicated in pancreatic cancer progression in experimental models, and may
constitute a therapeutic target, RON expression is not associated with prognosis or therapeutic responsiveness in
resected pancreatic cancer.
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Pancreatic cancer (PC) still remains one of the most
aggressive and lethal of human cancers, with a lack of
prognostic biomarkers and effective treatments contrib-
uting to its poor prognosis and high mortality. Around
15% of PC patients are eligible to undergo potentially
curative pancreatic surgery at the time of presentation.
However, those with operable PC still only have an
18–23% 5-year survival [1,2], with high incidences of
local recurrence and hepatic metastases occurring within
1–2 years after surgery [3]. This emphasizes the need for
adjuvant intervention. Gemcitabine is the current stand-
ard for post-operative chemotherapy and delays the de-
velopment of recurrent disease in some PC patients [4].* Correspondence: r.daly@garvan.org.au
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reproduction in any medium, provided the orOne explanation for why only a subset of PC patients re-
spond favourably to adjuvant treatment is the molecular
heterogeneity of PC [5]. The concept of stratifying
patients based on their molecular signatures has been
successful in breast cancer and is the basis of modern
clinical oncology [6]. Implementation of this treatment
strategy for PC may also prove beneficial. The literature
is replete with biomarkers of prognosis and therapeutic
responsiveness identified through small and/or single
pancreatic cancer patient cohorts. However, a recent sys-
tematic review has shown that very few of these have
been independently validated [7]. The calcium binding
protein S100A2 is one of the few prognostic biomarkers
where this is the case [7]. In PC, tumors that are nega-
tive for S100A2 have a significant survival benefit with
pancreatectomy compared to tumors with moderately-
high to high expression [8].
Recepteur d’origine nantais (RON), also referred to
as macrophage stimulating 1 receptor (MST1R), is a
receptor tyrosine kinase (RTK) and member of the
mesenchymal epithelial transition factor (MET)-proto-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors, RON is activated upon binding of its ligand, the
hepatocyte growth factor-like (HGFL) protein, also re-
ferred to as macrophage stimulating protein (MSP) and
macrophage stimulating 1 (MST1). HGFL is synthesized
from hepatocytes and secreted as an endocrine mediator
in an inactive precursor form called pro-MSP. Subse-
quently, the type II transmembrane proteinase MT-SP1,
also known as suppression of tumorigenicity 14 (ST14),
processes pro-MSP to its active form near the cell sur-
face, where it activates RON, leading to the initiation of
multiple signaling cascades that impact upon cellular
motility and survival [9].
RON is overexpressed in PC relative to the ductal
epithelium of non-malignant pancreas, and its signaling
enhances migration, invasion, and survival of PC cells
and promotes resistance to gemcitabine in experimen-
tal models, thus making it a potential therapeutic tar-
get and a possible marker of prognosis [10-12].
Although RON is associated with poor survival in gas-
troesophageal cancer [13] and a three-gene signature
involving RON, MSP, MT-SP1 is a strong indicator for
metastasis and poor prognosis in breast cancer [14],
the prognostic significance of RON in PC remains un-
known. The goal of this study was to use a compre-
hensive cohort of PC patients to assess RON as a
biomarker of prognosis and therapeutic responsiveness.Methods
Optimization of the RON antibody for
immunohistochemistry
Anti-RON β (C-20) antibody (Santa Cruz Biotechnol-
ogy) was used to immunoblot for RON expression
across a panel of PC cell lines; this antibody detects
full-length pro-RON (190 kDa), mature RON β-chain
(150 kDa), and a short form sf-RON isoform (55 kDa)
[15]. MIA PaCa-2 and Panc 10.05 were selected as
low-expressing and high-expressing controls for RON
expression, respectively, and were processed as forma-
lin-fixed, paraffin-embedded blocks and subsequently
sectioned at 4 μm onto positively charged slides
(Superfrost plus; Menzel-Glaser, Braunschweig, Germany).
Antigen was retrieved using DAKO S1699 solution in a
pressure cooker for 1 min. Immunostaining was per-
formed using a DAKO Auto-stainer. The slides were trea-
ted with 3% Peroxidase Block (DAKO, K4011) for 5 min
then Protein Block (DAKO, X0909) for 10 min and
stained with primary anti-RON β (C-20) antibody at a
dilution of 1:100 for 60 min. EnVision+ System anti-rabbit
(DAKO, K4003) was used as secondary antibody then
3,3'-diaminobenzidine (DAKO, K3468) was used as a sub-
strate. The slides were then counterstained with Mayer’s
haematoxyline.Patients, tissue microarrays, immunohistochemistry and
statistical analysis
Clinico-pathologic and outcome data for 492 conse-
cutive patients with a diagnosis of pancreatic ductal
adenocarcinoma who underwent pancreatic resection
were obtained from teaching hospitals associated with
the Australian Pancreatic Cancer Network [16] (Table 1).
This cohort consisted of a training set of 76 patients, a
validation set of 316 patients and a further cohort of
100 patients accrued prospectively for the International
Cancer Genome Consortium (ICGC) [17]. Detailed
methods for tissue microarray construction, the assess-
ment of immunostaining and statistical analysis were
described previously [8].
Immunostaining was performed on the training and
validation set using the anti-RON β (C-20) antibody as
described above. Positive RON expression was defined
as a modified histoscore (intensity x %) >210 as this
was the most discriminant cut-off point in the training
set. Median survival was estimated using the Kaplan-
Meier method and the difference was tested using the
log-rank Test. P values of less than 0.05 were consid-
ered statistically significant. Statistical analysis was per-
formed using StatView 5.0 Software (Abacus Systems,
Berkeley, CA, USA). Disease-specific survival was used
as the primary endpoint.
Expression array analysis
The pancreatic ICGC cohort consists of prospectively
acquired, primary operable, non-pretreated pancreatic
ductal adenocarcinoma samples [18]. For the ICGC
cohort, tumour cells were enriched by macro-dissection,
then RNA was extracted from tumors using Qiagen
AllprepW (Qiagen, Valencia, CA) in accordance with the
manufacturer's instructions, assayed for quality on an
Agilent Bioanalyzer 2100 (Agilent Technologies, Palo
Alto, CA), and hybridized to Illumina Human HT-12 V4
microarrays. mRNA expression data were available for
88 of 100 patients. Raw iDAT files were processed using
IlluminaGeneExpressionIdatReader (Cowley et al. manu-
script in preparation). Following array quality control,
data were vst transformed and robust spline normalized,
using the lumi R/Bioconductor package [19]. To confirm
the microarray probe quality, we: aligned the probe
sequences to the genome using UCSC BLAT [20]; and
also used an Illumina reannotation pipeline [21]. Both
methods confirmed that the probes for RON, MSP,
MT-SP1 perfectly and uniquely match the 3’ end of
the intended gene. The RON probe binds both full
length RON, and sf-RON. Expression levels of single-
gene (RON, MSP, MT-SP1), two-gene (RON+MSP)
and three-gene (RON+MSP+MT-SP1) combinations
were used to separate patients into two groups: high
for those patients with above-mean expression in all
Table 1 Clinico-pathological and outcome data corresponding to the pancreatic cancer tissue microarray training and
validation sets, and the prospective ICGC cohort gene expression array
Training Cohort Validation Cohort ICGC Cohort
Variables n= 76 No.
(%)
Median DSS
(months)
P value
(Logrank)
n = 316 No.
(%)
Median DSS
(months)
P value
(Logrank)
n= 100 No.
(%)
Median DSS
(months)
P value
(Logrank)
Sex
Male 45 (59.2) 16.3 157 (49.7) 18.3 61 (61.0) 18.4
Female 31 (40.8) 8.5 0.0340 159 (50.3) 16.9 0.5792 39 (39.0) 18.3 0.5467
Age (years)
Mean 62.1 66.7 66.9
Median 64.5 69.0 68.0
Range 35.0 – 83.0 28.0 – 87.0 34.0 – 90.0
Outcome
Follow-up (months) 0.3 – 158.0 0.1 – 195.8 0.1 – 29.8
Median follow-up 158.0 68.7 14.1
Death PC 68 (89.5) 259 (82.0) 33 (33.0)
Death other 5 (6.6) 15 (4.7) 9 (9.0)
Death Unknown 0 (0.0) 3 (0.9) 3 (3.0)
Alive 1 (1.3) 38 (12.0) 55 (55.0)
Lost to FU 2 (2.6) 1 (0.3) 0 (0.0)
Stagea
I 16 (21.1) 19.6 23 (7.3) 41.0 8 (8.0) 17.4
II 59 (77.6) 11.5 282 (89.2) 17.8 87 (87.0) 18.8
III 0 (0.0) 0 (0.0) 1 (1.0) ——b
IV 1 (1.3) 22.0 0.2828 11 (3.5) 7.6 <0.0001 4 (4.0) 12.0 ****c
T Stage
T1 12 (15.8) 16 (5.1) 3 (3.0)
T2 29 (38.2) 13.6 33 (10.4) 26.6 12 (12.0) 17.4
T3 35 (46.1) 14.7 0.4857 267 (84.5) 16.8 0.0084 84 (84.0)
T4 0 (0.0) 0 (0.0) 1 (1.0) 18.4 0.4297
N Stage
N0 37 (48.7) 19.8 119 (37.7) 21.2 24 (24.2) 17.4
N1 39 (51.3) 9.7 <0.0001 197 (62.3) 16.7 0.0267 75 (75.8) 18.4 0.4714
Grade
I 7 (9.2) 26 (8.2) 4 (4.0)
II 43 (56.6) 15.0 209 (66.1) 17.7 61 (61.0) ——
III 26 (34.2) 11.2 0.0283 81 (25.6) 18.3 0.5971 33 (33.0)
IV 2 (2.0) 15.1 0.0011
Tumor size
≤ 20 mm 15 (19.7) 17.1 77 (24.6) 32.0 14 (14.0) 18.3
> 20 mm 61 (80.3) 11.9 0.1232 236 (75.4) 16.0 <0.0001 86 (86.0) 18.4 0.8056
Margins
Clear 40 (52.6) 18.6 195 (61.7) 22.4 66 (66.0) ——
Involved 36 (47.4) 9.7 0.0004 121 (38.3) 13.3 <0.0001 34 (34.0) 13.9 0.0335
Tumor Location
Head 62 (81.6) 15.6 258 (81.6) 18.8 85 (85.0) 18.4
Others 14 (18.4) 7.4 0.0004 58 (18.4) 13.0 0.0312 15 (15.0) 13.6 0.0488
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Table 1 Clinico-pathological and outcome data corresponding to the pancreatic cancer tissue microarray training and
validation sets, and the prospective ICGC cohort gene expression array (Continued)
Perineural Invasion
Negative 24 (32.0) 15.6 82 (26.6) 25.6 20 (20.6) ——
Positive 51 (68.0) 13.6 0.1909 226 (73.4) 17.4 0.1180 77 (79.4) 17.4 0.0211
Vascular Invasion
Negative 45 (60.0) 15.0 161 (53.5) 21.2 39 (40.6) ——
Positive 30 (40.0) 10.1 0.0141 140 (46.5) 16.2 0.0070 57 (59.4) 15.9 0.0348
Adj Chemotherapy
Yes 13 (17.1) 13.6 98 (31.0) 22.4 65 (68.4) 21.4
No 63 (82.9) 14.1 0.7737 218 (69.0) 16.5 0.0451 30 (31.6) 12.0 0.0007
RON Expressiond
Low or absent 51 (79.7) 15.0 265 (94.3) 17.1 42 (52.5) 9.8
High 13 (20.3) 6.4 0.0409 16 (5.7) 18.3 0.2799 38 (47.5) 8.0 0.3830
Patient Cohorts Characteristics.
a AJCC 7th Edition.
b Median survival has not been reached yet.
c Rank test cannot be tested as one or more groups contained no censored observations.
d High RON expression was defined as H > 210 for immunohistochemistry or greater than 8.74 on normalized Log2 score for gene expression array.
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For RON, we also chose an 80% low : 20% high cut-
off to match that proportion of RON high patients in
the training cohort. Survival analysis was performed
using the Cox proportional hazards model, using the
survival package (version 2.36-9) in R (version 2.13.1).
Expression levels for all signatures were also analyzed
in a subset of 65 patients from the ICGC cohort,
which omitted patients with advanced disease.Figure 1 Western blot of pro-RON and RON β-chain expression acros
are low-expressing and high-expressing controls, respectively.Results
Optimization of anti-RON antibody for
immunohistochemistry
RON protein expression was determined by Western
blot analysis across a panel of PC cell lines (Figure 1).
All cell lines expressed RON, but at varying levels. These
results were used to select appropriate low-expressing
and high-expressing control cell line blocks for subse-
quent immunohistochemistry. MIA PaCa-2 was used ass a panel of pancreatic cancer cell lines. MIA PaCa-2 and Panc 10.05
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was used as the high-expressing control (Figure 2B). The
anti-RON antibody gave strong staining of a subset of
pancreatic cancers (Figure 2D, I & J) that was absent
upon use of control rabbit IgG (Figure 2C). Examples
where RON expression in pancreatic cancer was undetect-
able, or low, are also shown (Figure 2G and H). RON is
rarely expressed in the ductal cells of non-cancerous pan-
creas [3], so this was used as the negative-control tissue
(Figure 2E). RON is known to be overexpressed in breast
cancer [14], which provided an additional positive-control
tissue (Figure 2F). Staining was present in both membrane
and cytoplasm, which is consistent with past literature
[10,12].
RON expression in pancreatic cancer and its association
with patient prognosis
Three independent patient cohorts were utilized for this
study. Two of the cohorts, the training and validation
sets, which were acquired retrospectively, were immuno-
histochemically stained for RON expression. High RON
expression (H-score >210) was a biomarker of poor
prognosis in the training set (Figure 3A). However, in
the larger validation set RON expression was not prog-
nostic (Figure 3B). The evaluation of RON as aFigure 2 Optimization of RON immunohistochemical staining. Immun
(A and B), using IgG rabbit and anti-RON primary antibodies in pancreatic
and in breast cancer with high RON expression (E and F), at low and high
staining in pancreatic cancer tissue are also shown (G-J).predictive marker in the response to adjuvant gemcita-
bine therapy was not investigated in the training set as
this cohort pre-dates adjuvant gemcitabine given as
standard treatment. In the validation set, RON expres-
sion did not co-segregate with chemotherapy responsive-
ness, however a trend towards better qualitative
response was seen for the RON low or absent group
(Figure 4A & B).
Additionally, there was no association between RON
expression and tumor stage (Chi-squared P= 0.123),
tumor size (P= 0.629) lymph node metastases (P= 0.942),
grade (P= 0.332), perineural (P= 0.335) or vascular in-
vasion (P= 0.210).
RON mRNA was expressed in a continuous manner
over a third, prospectively acquired cohort, so two cut-
offs were used: a 50%:50% (Figure 5A), and an 80%:20%
(Figure 5B) low:high cutoff to match the frequency uti-
lized in the retrospective cohorts subjected to immuno-
histochemistry. At neither cutoff was RON associated
with prognosis. We omitted a group of patients with
more advanced disease (leaving n = 65), and again, RON
was not associated with prognosis (data not shown). In
addition, MSP or MT-SP1 expression (Figure 6A & B), a
two-gene expression signature of RON+MSP
(Figure 6C), and a three-gene expression signature ofohistochemical staining of RON in MIA PaCa-2 and Panc 10.05 cell lines
cancer tissues (C and D), and in benign ductal cells of the pancreas
magnification. Examples of absent, low, moderate to high RON
Figure 3 Kaplan-Meier survival curves for patients stratified
based upon RON expression in the training (n = 64, with n= 51
low and n=13 high) (A) and validation (n= 281, with n = 265
low and n=16 high) (B) cohorts. The p-value from fitting a Cox
proportional hazards model to the survival curves is indicated in the
plots.
Figure 4 Kaplan-Meier survival curves for patients stratified
according to adjuvant chemotherapy status with high RON
expression (n = 16) (A) and low or absent RON expression
(n= 265) (B) in the validation cohort (n = 281). The p-value from
fitting a Cox proportional hazards model to the survival curves is
indicated in the plots.
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gated, however, none of these signatures were associated
with prognosis.
Discussion
Pre-clinical studies identified RON as a potential pre-
dictive marker for gemcitabine response in pancreatic
cancer [11,12]. This study examined RON as a prognos-
tic and predictive biomarker in three large well-
annotated cohorts of patients (total of 492) with resect-
able PC using immunohistochemistry for the training
and validation set and gene expression arrays for the
ICGC cohort. Apart from the training cohort, RON ex-
pression was not associated with survival. The validation
cohort consisted of 316 patients and had a 99% power to
detect a hazard ratio of 1.90 (assuming it has a HR and
an expression pattern similar to the training cohort with
a Type I error of 0.05). However, RON overexpression
was only observed in 5.4% of patients in the validation
set as compared to 22.1% in the training set, but the
reason for the much lower proportion of RON over-
expressers in the validation set is not known. Theunexpected lower proportion of the over-expressers in
the validation cohort has reduced the power to detect a
difference and therefore, the inability to detect a differ-
ence may be due to a Type 2 error rather than there
being truly no difference between the two groups. A
post-hoc analysis of the validation set using different cut-
off points for RON expression could not demonstrate
any differential survival (data not shown). It is therefore
likely that due to the smaller number of patients, the
training cohort returned a false-positive result, which
highlights the importance of independent validation in
biomarker discovery and development.
Both the antibody used for IHC and the probe used
for mRNA analysis recognized the same RON isoforms:
the full-length inactive precursor pro-RON, the active
RON β-chain and short form sf-RON [15], thus enabling
comparisons to be made between the cohorts.
RON mRNA was expressed in a continuous manner in
the third, prospectively acquired cohort, so two cutoffs
were used: the mean (Figure 5A), and an 80%:20% low:
high cutoff to match the frequency utilized in the
restrospective cohorts (Figure 5B). Using both
approaches, RON was not associated with prognosis.
Additional to RON expression alone, a combination
Figure 5 Kaplan-Meier survival curves for patients stratified based upon RON mRNA expression in the prospectively accrued ICGC
cohort of PC (n = 88). Patients were split into two groups using a 50% low : 50% high cutoff (n = 44 in both groups) (A), or an 80% low : 20%
high cutoff (n = 70 and n= 18, respectively) which matches the cutoff found using protein expression in the training cohort (B). The p-value from
fitting a Cox proportional hazards model to the survival curves is indicated in the plots.
Figure 6 Kaplan-Meier survival curves for patients stratified based upon mRNA expression levels of MSP (A), MT-SP1 (B), a two-gene
signature combination of RON+MSP expression (C), and a three-gene signature combination of RON+MSP+MT-SP1 expression (D)
from the prospectively accrued ICGC cohort (n = 88). All genes use a 50%:50% low:high cutoff. The p-value from fitting a Cox proportional
hazards model to the survival curves is indicated in the plots.
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http://www.biomedcentral.com/1471-2407/12/395gene signature of RON, MSP and MT-SP1, which is
prognostic for breast cancer, was also evaluated. How-
ever, in PC this three-gene signature, and even two-gene
signature combinations, did not correlate with patient
survival. We acknowledge that there is reduced power in
the 2-gene and 3-gene signatures due to low sample
numbers in each strata, but it should be noted that this
is the largest prospectively accrued cohort of PC patients
with mRNA data to date. Collectively, this suggests that
the role of RON is cancer-type specific and that RON is
unlikely to be a major metastatic driver in PC. However,
the ICGC cohort is still relatively young, currently with
a median follow up of 14.1 months, and exhibits rela-
tively small numbers. Therefore, the negative result can
also possibly be due to the study being under-powered.
Data from this study do not support RON as a prog-
nostic or predictive biomarker in resectable PC. This
study, however, did demonstrate that RON is expressed
in a large proportion of PC (training set: 61 of 64, 95.3%;
validation set: 253 of 281, 90.0%), which is consistent
with previous published data [10]. Due to increased ex-
pression during PC progression RON may still prove to
be an effective therapeutic target.
To improve the efficiency of gemcitabine in PC, sev-
eral studies have evaluated the co-administration of
gemcitabine with other cytotoxic and biological agents
[22,23]. However, the epidermal growth factor receptor
(EGFR) inhibitor, erlotinib, was the only agent to show
efficacy in a phase III setting [24]. The EGFR is com-
monly overexpressed in PC and is associated with poor
prognosis and disease progression [25]. The frequent
overexpression of RON in PC suggests that it could also
be a target for therapy. Supporting this concept, silen-
cing RON expression reduced growth of pancreatic can-
cer xenografts and increased gemcitabine-induced
apoptosis [11]. In addition, function-blocking monoclo-
nal antibodies and small molecular inhibitors directed
against RON have demonstrated promising results in
pre-clinical models [10,26,27].
Conclusion
RON is not associated with prognosis or therapeutic re-
sponsiveness in resectable PC, in the current cohorts of
patients. However it may still represent a therapeutic
target in this disease.
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